



IV INTERNATIONAL
**THORACIC CANCER
DEBATES**
30 - 31 January, 2026

INTERNATIONAL THORACIC CANCER DEBATES 2026
January 30th & January 31st, 2026, Canary Islands
Fundación Canaria de Cáncer de Pulmón

PRELIMINARY PROGRAM

SCIENTIFIC COORDINATORS

Dr. Rosario García Campelo, Complejo Hospitalario Univ. de A Coruña
Dr. Luis Paz-Ares. Hospital Univ. 12 de Octubre. Madrid
Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA
Dr. Delvys Rodríguez Abreu. Hospital Univ. Insular, Las Palmas de Gran Canaria

Friday 30th January

08:55 – 09:10 Welcome and official opening

09:10- 09:30 Lecture: SCLC from biology to future?

Dr. Luis Paz-Ares. Hospital Universitario 12 de Octubre. Madrid

Chairs: Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA

09:30 – 09:40 Discussion

09:40 – 11:05 SESSION I. Early stages with AGAs NSCLC

Chairs: Dr. Pilar Garrido. Hospital Univ. Ramon y Cajal, Madrid

Dr. Federico Cappuzzo. Instituto Nazionale Tumore Regina Elena, Roma. Italy

Early stage: neoadjuvant and adjuvant

09:40 – 09:55 In EGFRm NSCLC: Neoadjuvant or Adjuvant therapy or both.?

Dr. Narjust Flores. Dana-Farber Cancer Institute, Boston, USA

09:55 – 10:10 What about ALK and others?

Dr. Lorenza Landi. Instituto Nazionale Tumori Regina Elena, Rome. Italy

10:10 – 10:20 Challenges of using and adapting MRD in lung cancer

Dr. Luis E. Raez. Memorial Cancer Institute at Memorial Healthcare System, Florida, USA

10:20 – 11:00 Panel Discussion

Dr. Margarita Majem. Hospital de la Santa Creu i Sant Pau. Barcelona

Dr. Ernest Nadal. ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona

Dr. Enric Carcereny. ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona

Dr. Jesús Corral. Hospital Univ. de Jerez de la Frontera, Cádiz

11:00 – 11:25 COFFEE BREAK

11:25 – 13:05 SESSION I. *Advanced stage 1st line with AGAs*

Chairs: Dr. Rosario García. Complejo Hospitalario Univ. de A Coruña
Dr. Rafael Rosell. Hospital Univ. Dexeus, Barcelona

11:25 – 11:40 Advanced EGFRm: which combo/ which patient?

Dr. Daniel Tan. National Cancer Centre Singapore

11:40 – 11:55 From Success to Resistance: Managing Progression in EGFR-Mutant Lung Cancer

Dr. Pasi Jänne. Dana-Farber Cancer Institute, Boston, USA

11:55 – 12:10 Exon 20 insertions. Not so uncommon disease but different treatments?

Dr. Natasha Leighl. Hospital Princess Margaret Cancer Centre, Toronto, Canada

12:10 – 12:25 HER2 deregulated NSCLC. ADC or TKIs treatment?

Dr. Rosario García Campelo, Complejo Hospitalario Univ. de A Coruña

12:25 – 12:40 KRAS which one is the winning strategies in the future.

Dr. Jordi Remon. Institute Gustave Roussy, Paris, France

12:40 – 13:20 Panel Discussion. All the authors

Dr. Noemi Reguart. Hospital Clinic Barcelona

Dr. Antonio Calles. Hospital General Univ. Gregorio Marañón, Madrid

Dr. Oscar Juan. Hospital Univ. y Politécnico La Fe, Valencia

Dr. Reyes Bernabé. Hospital Univ. Virgen del Rocío, Sevilla

13:20 – 14:10 LUNCH BREAK (Foto de familia 13:30-13:35)

14:10 – 15:50 SESSION 2. *Metastatic NSCLC other mutations*

Chairs: Dr. Bartomeu Massuti. Hospital General Univ. Dr. Balmis, Alicante
Dr. Javier de Castro. Hospital Univ. La Paz, Madrid

14:10 – 14:25 How to move forward from CROWN in ALK+ NSCLC?

Dr. Tony Mok. State Key Laboratory of South China, Chinese Univ. Hong Kong, China

14:25 – 14:40 News in the ROS1 and RET world.

Dr. Jessica Lin. Massachusetts General Hospital, USA

14:40 – 14:55 NTRK, BRAF and MET + NSCLC. What is new?

Dr. Enriqueta Felip. Hospital Univ. Vall d'Hebron, Barcelona

14:55 – 15:35 Panel Discussion

Dr. Martín Lázaro. Hospital Álvaro Cunqueiro, Vigo

Dr. Santiago Viteri. UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona

Dr. Dolores Isla. Hospital Univ. Lozano Blesa, Zaragoza

Dr. Emilio Esteban. Hospital Universitario Central de Asturias

15:35 – 15:50 COFFEE BREAK

15:50 – 17:50 SESSION 3. IMMUNOTHERAPY IN NSCLC. Localize disease

Chairs: Dr. Luis Paz-Ares. Hospital Univ. 12 de Octubre. Madrid

Dr. Edgardo Santos. The Oncology Institute of Hope and Innovation, Florida, USA

15:50 – 16:05 The Path to lung cancer cure. What is beyond the traditional approaches?

Dr. Jarushka Naidoo. Beaumont RCSI Cancer Centre, Dublin, Ireland

16:05 – 16:20 Expanding/Redefining the role of surgery in IO era.

Dra. Cecilia Pompili. Hull York Medical School, York, United Kingdom

16:20 – 16:35 Any new real IO biomarkers on scene

Dr. Sanjay Popat. Royal Marsden Hospital, London, United Kingdom

16:35 – 17:15 Panel Discussion

Dr. Helena Linardou. Metropolitan Hospital, Athens, Greece

Dr. José Ramón Cano. Hospital Univ. Insular, Las Palmas de Gran Canaria

Dr. Sergio Vázquez. Hospital Univ. Lucus Augusti, Lugo

Dr. Edgardo Santos. The Oncology Institute of Hope and Innovation, Florida, USA

17:15 – 17:40 SESSION 4. Economic and Technological Perspectives in Lung Cancer

Chairs: Dr. D. Lluís Serra Majem. Rector Magnífico Univ. de Las Palmas de Gran Canaria

PH.D. Beatriz González López-Valcárcel. Univ. de Las Palmas de Gran Canaria

17:15 – 17:30 The economic unfeasibility of personalized medicine in Lung cancer

Pietro Veronesi. Professor of Finance at the University of Chicago, USA

17:30 – 17:45 AI agent for healthcare: from usability to sustainability

Dr. Arsela Prelaj. Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

17:45 – 18:25 Discussion

18:25 CLOSING

09:30 – 12:30 SESSION 5. Small cell carcinoma

Chairs: Dr. Rolf Stahel. ETOP IBCSG Partners Foundation, Berne, Switzerland
Dr. Helena Linardou. Metropolitan Hospital, Athens, Greece

09:30 – 09:45 Redefining the front-line standards in SCLC

Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA

09:45 – 10:00 Relapsed SCLC: Breaking the Limits, Redefining Boundaries

Dr. Giannis Mountzios. Henry Dunant Hospital Center. Athens, Greece

10:00 – 10:15 Re-thinking Limited-Stage SCLC: Is a paradigm shift finally here?

Dr. Joachim Aerts. Pulmonary Medicine Erasmus MC in Rotterdam, Netherlands

10:15 – 10:30 Discussion and Q&A

Dr. José Manuel Trigo. Hospital HC Marbella, Malaga

Dr. Manuel Domine. IIS-FJD. Oncohealth Institute, Madrid

Dr. Anna Estival. Hospital Univ. Insular, Las Palmas de Gran Canaria

10:30 - 10:50 COFFEE BREAK

10:50 – 11:50 SESSION 6. ADCs double molecules.

Chairs: Dr. Delvys Rodriguez Abreu. Hospital Univ. Insular, Las Palmas de Gran Canaria
Dr. Enriqueta Felip. Hospital Univ. Vall d'Hebron, Barcelona

10:50 – 11:05 What is the right place for anti Trop2 ADCs.

Dr. Marina Garassino. University of Chicago, Chicago

11:05 – 11:20 Emerging ADCs. New generations?

Dr. Martin Reck. LungenClinic Grosshansdorf, Hamburg, Germany

11:20 – 11:35 Cell Therapy, CAR T and vaccines

Dr. Jon Zugazagoitia. Hospital Univ. 12 de Octubre, Madrid

11:35 – 11:50 Discussion and Q&A

Dr. Federico Cappuzzo. Istituto Nazionale Tumore Regina Elena, Roma. Italy

Dr. Manuel Cobo. Hospital Regional Univ. de Málaga

Dr. Ana Laura Ortega Granados. Hospital Univ. de Jaén, Andalucia

11:50 – 13:55 SESSION 7. Bispecific. doubles the future.

Chairs: Dr. Santiago Ponce. Hospital Univ. 12 de Octubre, Madrid

Dr. Luis Ángel León. Hospital Clínico Univ. Santiago de Compostela

11:50 – 12:05 Biology, why is the sum greater than its parts?

Dr. Jair Bar. School of Medicine, Tel Aviv University, Tel Aviv, Israel

12:05 – 12:20 Knocking on Two Doors: BsAbs Modulating Immune Checkpoints in NSCLC

Dr. Solange Peters. Univ. Hospital of Lausanne, Switzerland

12:20 – 12:35 Bispecific Antibodies That Starve and Activate: PD-1 and VEGF Dual Blockade

Dr. Delvys Rodríguez Abreu. Hospital Univ. Insular, Las Palmas de Gran Canaria

12:35 – 12:50 Management of emerging toxicities (ADC, bispecific and T-cell engager)

Dr. Arancha Manzano. Hospital Univ. 12 de Octubre. Madrid

12:50 – 13:05 Panel Discussion

Dr. Antonio Araujo. Hospital Univ. Oporto, Portugal

Dr. Pilar Garrido. Hospital Univ. Ramón y Cajal, Madrid

Dr. Oscar Juan. Hospital Univ. Politécnico La Fe, Valencia

13:05 – 13:15 CLOSING REMARKS